ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation. ESSA Pharma’s rating score has improved by 40.1% from three months ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus price target of $5.10 for the company, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 184 out of 265 based on the ratings given to related companies.
Several equities research analysts have recently issued reports on EPIX shares. Bloom Burton upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, January 18th. Zacks Investment Research upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research note on Tuesday, January 16th. Finally, ValuEngine upgraded shares of ESSA Pharma from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings data on Monday, December 11th. The company reported ($0.09) earnings per share (EPS) for the quarter. analysts anticipate that ESSA Pharma will post -0.29 earnings per share for the current year.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.